Holen Sie sich die Stockscreener-App
118.97
0.42%
-0.50
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$119.47
Offen:
$119.59
24-Stunden-Volumen:
1.39M
Relative Volume:
1.48
Marktkapitalisierung:
$11.36B
Einnahmen:
$1.64B
Nettoeinkommen (Verlust:
$121.85M
KGV:
-15.19
EPS:
-7.83
Netto-Cashflow:
$-480.40M
1W Leistung:
-3.83%
1M Leistung:
+7.32%
6M Leistung:
-3.67%
1J Leistung:
+31.76%
1-Tages-Spanne:
$118.56
$121.00
1-Wochen-Bereich:
$117.97
$128.73
52-Wochen-Spanne:
$89.92
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie SRPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
118.97 | 11.36B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Nippon Owes $115M In Muscular Dystrophy IP Fight, Jury Says - Law360
Nippon Shinyaku Owes Sarepta $115 Million on Gene-Therapy Patent - Bloomberg Law
Sarepta Wins First Phase of Nippon Shinyaku Gene-Therapy Trial - Bloomberg Law
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder - MSN
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam - Yahoo Finance
Communiqué de presse - GlobeNewswire Inc.
Sarepta completes subject dosing in Phase III LGMD2E/R4 therapy trial - Yahoo Finance
Sarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC Wainwright - MarketBeat
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts - Benzinga
Even though Sarepta Therapeutics (NASDAQ:SRPT) has lost US$491m market cap in last 7 days, shareholders are still up 33% over 1 year - Simply Wall St
Sarepta Completes Pivotal Phase 3 Trial Enrollment for Groundbreaking Muscular Dystrophy Gene Therapy - StockTitan
National Bank of Canada FI Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Sells $1,310,820.00 in Stock - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Geode Capital Management LLC - MarketBeat
Stifel Financial Corp Grows Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics' SWOT analysis: DMD leader's stock poised for growth - Investing.com
19,358 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Bought by World Investment Advisors LLC - MarketBeat
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Yahoo Finance
Garden State Investment Advisory Services LLC Buys Shares of 16,936 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst - Benzinga
FDA’s new accelerated approval guidance to benefit rare disease drug development, analysts believe - Proactive Investors USA
Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High? - Yahoo Finance
Y Intercept Hong Kong Ltd Sells 29,809 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
HighTower Advisors LLC Sells 10,327 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Two Sigma Advisers LP Lowers Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Point72 Asset Management L.P. Cuts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Main Management ETF Advisors LLC Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Wellington Management Group LLP Purchases 665,087 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Kathryn Jean Boor Sells 1,636 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock - MarketBeat
Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report? - MSN
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sarepta therapeutics director sells $205,399 in stock - Investing.com India
Sarepta therapeutics director sells $205,399 in stock By Investing.com - Investing.com Nigeria
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Soros Fund Management LLC Acquires Shares of 206,583 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Duchenne Muscular Dystrophy Pipeline Insights 2024: - openPR
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 33,278 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta, Biotech’s Regulatory Go-Getter, Signs Standout Rare Disease Deal - BioSpace
The Manufacturers Life Insurance Company Has $9.34 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta to develop Arrowhead’s muscular dystrophy treatments - Muscular Dystrophy News
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing… - MSN
Sarepta gains rights to Arrowhead Huntington’s treatment candidate - Huntington's Disease News
Sarepta Therapeutics' SWOT analysis: gene therapy leader's stock poised for growth - Investing.com
Edgestream Partners L.P. Takes $2.31 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Zacks Research Has Positive Forecast for SRPT Q1 Earnings - MarketBeat
Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio? - Benzinga
Erste Asset Management GmbH Purchases Shares of 636,065 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Bellevue Group AG - MarketBeat
Point72 Europe London LLP Invests $872,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Braidwell LP Sells 42,777,500 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sarepta Therapeutics Inc-Aktie (SRPT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wigzell Hans Lennart Rudolf | Director |
Dec 12 '24 |
Sale |
124.84 |
10,500 |
1,310,820 |
22,840 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):